The Swiss company markets the WAVE system, a waveguide interferometry-based instrument for studying molecular interactions in real time.
The companies will offer customers a way to mine 23andMe's customer base for subjects with specific genetic or clinical features, and design and conduct a trial around them.
The Seattle startup is looking to partner with pharmaceutical companies and offer its yeast fusion sequencing technology as a contracted research service.
The partners will use Adaptive's ClonoSeq assay to assess minimal residual disease in several of Amgen's hematology drug development programs.
Interpace Diagnostics subsidiary Interpace BioPharma will perform services worldwide, while Genecast will offer the services in China.
Personalis will analyze samples from the study, evaluating the pharma company's novel therapy INVAC-1 either as a monotherapy or in combination with the TKI ibrutinib.
The firm is developing a biomarker panel to detect mutations in mesenchymal cells, with the goal of guiding drug treatment and improving earlier patient intervention.
The combined company will use RNA-based tools to enhance drug development by identifying the right patients for oncology drugs and potentially improving drug response rates.
The international firm is one of several pharmaceutical companies emphasizing new single-cell technologies to improve existing drugs and find new ones.
In its first quarter operating as a public company, the Seattle-based immune sequencing firm more than tripled development revenues and grew sequencing revenues.
In a Phase II trial, Sophia will look for genomic markers of clinical response to ADC's treatment for relapsed or refractory diffuse large B-cell lymphoma.
QGel is looking to raise $60 million to begin clinical testing of its technology for pharmaceutical product development for targeted cancer therapy.
NEC said the deal will bolster its cancer immunotherapy development programs, which are focused on ovarian cancer and head and neck cancer.
The grant recipients will receive up to $5 million each and are led by scientists at institutions including Harvard Medical School and the Cleveland Clinic.
The firm is using automated laboratory testing, artificial intelligence, and single-cell omics for a "precision" approach to cancer drug discovery.
The assets include intellectual property relevant to iPSC-based phenotypic drug discovery and an existing product business around iPSC-derived cells.
The partners will offer drug discovery services based on human induced pluripotent stem cells and cells derived from these.
Novel clinical trials designs are enabling exploration of new precision oncology drug indications in Japan and China, and increasing patient access to treatments.
SpeeDx said it will work with GlaxoSmithKline on tests to support its antibiotic clinical trials, as well as its new product development efforts.
The firm is validating two biomarkers that it hopes will stratify patients for its investigational drug for pediatric minimally verbal autism.
At the Lancet, more than two dozen public health researchers condemn the conspiracy theories that have emerged surrounding the source of the COVID-19 outbreak.
The Washington Post reports that Philip Leder, who helped uncover how DNA codes for proteins and studied the role of genes in cancer, has died.
Researchers from Trinity College Dublin and the University of Pittsburgh look into how often de novo genes arise and how important they may be.
In Nucleic Acids Research this week: pipeline for genotyping Alu retrotransposon mobile element insertions, previously undocumented non-coding RNAs, and more.